The Skidki-na-vse® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
Cancer Drug Costs May Not Be Factored Into Reimbursement
Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.
Skidki-na-vse Continuing Education™ Announces Keynote Speakers for Directions in Oncology Pharmacy™ Fall Conference Series
The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.
Report: Racial Disparity Continues in Breast Cancer
The black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades.
Generic Fulvestrant Injection Launched for Breast Cancer Monotherapy in Post-Menopausal Women
Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.
ClarIDHy Trial: First Targeted Therapy to Improve Outcomes in Cholangiocarcinoma
Ivosidenib improved progression-free survival with a promising trend toward improved overall survival in patients with IDH1-mutated cholangiocarcinoma.
Overall Survival, PFS Data Reported for Apalutamide in Non-metastatic CRPC at ESMO
Apalutamide (Erleada) showed an overall survival benefit in patients with non-metastatic castration-resistant prostate cancer.
Immunotherapy Toxicity: Strategies for Monitoring, Treating Adverse Events
A session at the ESMO Congress 2019 highlighted potential prevention and treatment strategies for life-threatening immunotherapy toxicities in patients with cancer.
Precision Medicine in Oncology: More Strategies for Identifying Patients Needed
At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen, discussed the increasing value of precision medicine in oncology and what will be needed to facilitate the use of precision medicine as more agents become available. 
Challenges in Treating TRK Fusion Cancer
At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen explained the challenges in identifying and treating TRK fusion cancer in patients. 
High Response Rate, Durability Maintained With Larotrectinib in TRK Fusion Cancer
New data confirm high activity of larotrectinib in pediatric and adult patients with TRK fusion cancer.
Costs for Many Novel Cancer Drugs Not Aligned With Clinical Value in US, Europe
With more novel therapies entering the market, costs are on the rise, however, new research suggests that the price tag may not reflect the drug’s clinical value.
+ Load More